MXCT.L - MaxCyte, Inc.

LSE - LSE Delayed Price. Currency in GBp

MaxCyte, Inc.

22 Firstfield Road
Suite 110
Gaithersburg, MD 20878
United States
301-944-1700
http://www.maxcyte.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas Arthur DoerflerCo-Founder, Pres, CEO & Exec. Director644.38kN/A1956
Mr. Ronald Evan HoltzCFO, Company Sec. & Director414.48kN/A1958
Mr. Maher MasoudVP of LegalN/AN/AN/A
Mr. Thomas Michael RossExec. VP of Global SalesN/AN/A1961
Mr. Markus J. HunkelerVP of MarketingN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers, as well as transfection insourcing services. In addition, it develops CARMA, a messenger ribonucleic acid autologous platform for immune-oncology that enables manufacture and controllable delivery of next-generation chimeric antigen receptor engineered T/NK-cell therapies for a range of cancer indications, including solid tumors. The company licenses and sells its instruments and technology; and sells its disposable processing assemblies to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. It has a cooperative research and development agreement with the National Institutes of Health's and National Institute of Allergy and Infectious Diseases to develop treatments for X-linked chronic granulomatous disease using gene correction leveraging CRISPR/Cas9; and a research agreement with Kite Pharma, Inc. to enable non-viral cell engineering. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

MaxCyte, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.